Skip to Content
Søk Menu

HER2-negative Breast Cancer – A Pathologist’s Perspective

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Relaterat innehåll

Peeter Karihtala

The Clinical Value of Immuno-Oncological Treatments in Early Breast Cancer

/ Peeter Karihtala
Bröstcancer Play the Video 09:38

LBA20: Sacituzumab Govitecan Significantly Prolongs PFS versus Chemotherapy in Advanced Triple-Negative Breast Cancer

/ Jan Andreasen
BröstcancerESMO25NBCN
John Crown

ESMO 2025: Ribociclib + NSAI Reduced the Risk of Invasive and Distant Recurrence of HR+/HER2−Early Breast Cancer

/ John Crown
BröstcancerESMO25NBCN Play the Video 03:24
Charles Geyer

ESMO 2025: Paradigm Shift in Breast Cancer Treatment

/ Charles E Geyer Jr.
BröstcancerESMO25NBCN Play the Video 05:53

ESMO 2025: Treatment with CDK4/6 Inhibitors Extending Their Benefit and Reinforcing the Value for Patients with High-Risk HR+, HER2-Negative Early Breast Cancer

/ Jan Andreasen
BröstcancerESMO25NBCN

ESMO 2025: A Potential New Anthracycline-Free Neoadjuvant Regimen for Patients with High-Risk HER2-Positive Early Breast Cancer

/ Jan Andreasen
BröstcancerESMO25NBCN
Alan Celik

Palbociclib As First-Line Breast Cancer Treatment: A Danish Perspective

/ Alan Celik
Bröstcancer Play the Video 06:19
Dimitrios Salgkamis

ESMO Breast Cancer 2025: Potential Biomarkers Linked to Hematologic Toxicity

/ Dimitrios Salgkamis
BröstcancerNBCN Play the Video 05:35
Anders Winther Mølby Nielsen

New Data Support Boost in ER-/HER2- Breast Cancer

/ Anders W. Mølby Nielsen
BröstcancerNBCN Play the Video 08:40
Back to top